First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

Abstract

In this podcast, over a series of four parts, the authors provide an overview of the CheckMate 9DW study (NCT04039607) in hepatocellular carcinoma (HCC) and their opinions on how it impacts the treatment landscape for first-line unresectable HCC. The first two parts provide an overview of the primary safety and efficacy data from CheckMate 9DW as well as key sub-group analyses and additional findings. The third part focuses on the early crossing phenomenon of the overall survival Kaplan-Meier (KM) curves and discussion of potential contributors. The fourth part discusses the management of adverse events, the timing of immune‑mediated adverse events, and the impact of discontinuation and steroid use on efficacy. Across all parts, implications for clinical practice will be discussed, including topics such as patient selection, sequencing of therapies, immune-mediated toxicities, monitoring recommendations, and real-world considerations.